AVITA Medical Inc represents a values-driven corporate philosophy focused on transforming lives through innovative medical solutions. The company prioritizes patient-centric healthcare and aims to deliver cutting-edge regenerative products and technologies. AVITA Medical Inc is dedicated to providing advancements in the field of regenerative medicine, particularly in the treatment of acute and chronic wounds. By combining science, medical expertise, and compassion, AVITA Medical Inc strives to improve patient outcomes and enhance quality of life. As a leader in regenerative medicine, AVITA Medical Inc remains committed to sustainability, ethical practices, and driving meaningful change in the healthcare industry.

AVITA Medical Inc primarily operates in the United States, Europe, and Australia.

AVITA Medical Inc has achieved significant milestones in its journey. One notable accomplishment includes the FDA approval of its flagship product, RECELL® System, in September 2018. This innovative regenerative medicine device is used for the treatment of acute thermal burns in patients. Additionally, AVITA Medical Inc successfully established partnerships with leading medical centers and institutions globally, facilitating the adoption and utilization of the RECELL System. The company has also significantly expanded its global presence by securing market approvals in various countries. AVITA Medical Inc continues to make advancements in regenerative medicine, revolutionizing burn treatment and positively impacting patients' lives.

AVITA Medical Inc. is a leading regenerative medicine company that specializes in the development and commercialization of innovative therapies for a range of skin conditions. Founded in 2002, AVITA Medical has grown into a globally recognized and respected company in the field. It is dedicated to utilizing its proprietary technology platform, the RECELL® System, to provide innovative and transformative solutions for patients with burns, chronic wounds, and aesthetic conditions. With a strong commitment to research and development, AVITA Medical continues to expand its product portfolio and improve patients' lives worldwide through its cutting-edge regenerative medicine treatments.

The main competitors of AVITA Medical Inc in the market include companies such as Acelity (formerly known as KCI), Molnlycke Health Care, Smith & Nephew, and Dermatix.

AVITA Medical Inc is primarily active in the healthcare and biotechnology industries. With a focus on regenerative medicine solutions, AVITA Medical specializes in developing and commercializing innovative treatments for wounds, burns, and other skin-related conditions. Through its proprietary technology called the RECELL® System, the company aims to revolutionize the way healthcare professionals offer personalized skin regeneration solutions. AVITA Medical Inc's commitment to advancing patient care within the healthcare and biotech sectors has positioned it as a leader in the field, with its products offering promising benefits and potential advancements in wound healing and skin restoration.

AVITA Medical Inc is a regenerative medicine company that specializes in developing and commercializing innovative treatments for a variety of skin defects and conditions. Their business model revolves around leveraging their proprietary technology, known as the RECELL® System, which enables the rapid and efficient regeneration of skin cells. AVITA Medical aims to transform the lives of patients by providing advanced solutions for burns, chronic wounds, and aesthetic indications. Through collaborations, research, and a patient-centered approach, AVITA Medical Inc strives to improve outcomes and quality of life for individuals in need of effective skin restoration.

AVITA Medical P/E suhe on −7,92.

AVITA Medical KUV on 2,76.

AlleAktien kvaliteediskoor ettevõttele AVITA Medical on 4/10.

oodatud AVITA Medical käive on 74,00 mln. USD.

oodatud AVITA Medical kasum on −25,80 mln. USD.

AVITA Medical Inc is a leading company in the field of regenerative medicine, offering a wide range of products and services. The company's business model is based on three main divisions: the development and marketing of innovative and effective regenerative medicine products, the provision of wound care services, and the distribution of products and devices for medical applications. The first division of AVITA Medical's business model is the development and marketing of regenerative medicine products. The company specializes in the production of dermographs used to treat patients with severe skin injuries or defects. The company's core technology platform is the RECELL system, an automated and portable unit for producing cell therapy products from the patient's fresh tissue. Using this technology, the company can produce customized therapeutic products for a variety of applications, including burns, chronic wounds, and skin reconstruction. The second division of AVITA Medical's business model is the provision of wound care services. The company offers a wide range of services tailored to the needs of patients with severe skin injuries or defects. These services include surgical procedures, conservative wound care, and other measures to accelerate wound healing and improve skin regeneration. The third division of AVITA Medical's business model is the distribution of products and devices for medical applications. The company distributes a wide range of medical devices and accessories, including instruments for the application of the RECELL system and dermographs. In addition, customers can also access training and consulting services to ensure the proper use of the devices and products. Overall, AVITA Medical Inc is committed to improving the treatment of patients with serious skin injuries and defects, and to providing them with a better quality of life. The company has developed a wide range of products and services tailored to the needs of these patients. By utilizing the company's advanced technology platform, doctors and surgeons can produce customized therapeutic products specifically tailored to the needs of each individual patient, thereby reducing treatment duration and accelerating healing. AVITA Medical strives to continuously improve its products and services and develop new innovations to further enhance the treatment of patients with skin injuries and defects.

AVITA Medical maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu AVITA Medical jaoks arvutada või ettevõte ei maksa dividende välja.

AVITA Medical ISIN on US05380C1027.

AVITA Medical WKN on A2P733.

AVITA Medical tähis on RCEL.

Viimase 12 kuu jooksul maksis AVITA Medical dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab AVITA Medical tõenäoliselt dividendi summas 0 USD.

AVITA Medical praegune dividenditootlus on .

AVITA Medical maksab kvartaalset dividendi. See makstakse välja kuudel .

AVITA Medical maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

AVITA Medical on liigitatud sektorisse 'Tervis'.

Viimase AVITA Medical dividendide saamiseks 7.7.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 7.7.2024.

Viimane dividendimakse toimus 7.7.2024.

Aastal 2023 maksis AVITA Medical 0 USD dividende.

AVITA Medical dividendid makstakse välja USD.